Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

[1]  M. Caraglia,et al.  Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells , 2014, Cell Death and Disease.

[2]  K. Anderson,et al.  Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. , 2013, Leukemia research.

[3]  S. Sultana,et al.  Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP Kinase and NF-κB. , 2013, Experimental and molecular pathology.

[4]  M. Caraglia,et al.  Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells , 2013, Cell Death and Disease.

[5]  T. Kubo,et al.  Zoledronic acid significantly enhances radiation‑induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. , 2013, International journal of oncology.

[6]  L. Zheng,et al.  HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway , 2013, Cell Death and Disease.

[7]  J. Forbes,et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  P. L. Bergsagel,et al.  Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.

[9]  G. Morgan,et al.  Effects of bone-targeted agents on cancer progression and mortality. , 2012, Journal of the National Cancer Institute.

[10]  K. Anderson.  The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Logothetis,et al.  Novel therapies for metastatic castrate-resistant prostate cancer. , 2011, Journal of the National Cancer Institute.

[12]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[13]  F. Bruzzese,et al.  Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep‐2 cancer cells , 2011, Proteomics.

[14]  M. Caraglia,et al.  HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT , 2011, Journal of cellular physiology.

[15]  R. Sutherland,et al.  Pathways of chemotherapy resistance in castration-resistant prostate cancer. , 2011, Endocrine-related cancer.

[16]  J. Mönkkönen,et al.  Biochemical and molecular mechanisms of action of bisphosphonates. , 2011, Bone.

[17]  N. Normanno,et al.  Pharmacokinetic evaluation of zoledronic acid , 2011, Expert opinion on drug metabolism & toxicology.

[18]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[19]  R. Franco,et al.  Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase , 2010, British Journal of Cancer.

[20]  T. Morii,et al.  Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. , 2010, Anticancer research.

[21]  H. Scher,et al.  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer , 2010, Cancer Chemotherapy and Pharmacology.

[22]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Desideri,et al.  Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis , 2009, Molecular Cancer Therapeutics.

[24]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[25]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[26]  P. Delrio,et al.  Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed , 2009, Cancer biology & therapy.

[27]  Mark B. Jones,et al.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. , 2008, Journal of the National Cancer Institute.

[28]  D. Qian,et al.  Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors , 2008, Clinical Cancer Research.

[29]  M. Ochi,et al.  Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells , 2008, Cancer Chemotherapy and Pharmacology.

[30]  J. Beck,et al.  Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro , 2007, Molecular Cancer Therapeutics.

[31]  P. Lehenkari,et al.  Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. , 2007, European journal of pharmacology.

[32]  A. Cuenda,et al.  p38 MAP-kinases pathway regulation, function and role in human diseases. , 2007, Biochimica et biophysica acta.

[33]  M. Marra,et al.  R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation , 2007, Journal of cellular physiology.

[34]  M. Marra,et al.  Emerging anti-cancer molecular mechanisms of aminobisphosphonates. , 2006, Endocrine-related cancer.

[35]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[36]  G. Tortora,et al.  Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. , 2005, Endocrine-related cancer.

[37]  J. Molkentin,et al.  The DnaJ-Related Factor Mrj Interacts with Nuclear Factor of Activated T Cells c3 and Mediates Transcriptional Repression through Class II Histone Deacetylase Recruitment , 2005, Molecular and Cellular Biology.

[38]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Kamphuis,et al.  Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[41]  S. Kimura,et al.  The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. , 2003, Blood.

[42]  W. Miller,et al.  The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function , 2003, Journal of clinical pharmacology.

[43]  P. Chieffi,et al.  EPN: A novel epithelial cell line derived from human prostate tissue , 2002, In Vitro Cellular & Developmental Biology - Animal.

[44]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Mönkkönen,et al.  Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. , 1999, Molecular pharmacology.

[46]  H. Kung,et al.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. , 2011, American journal of cancer research.

[47]  海津 完也.  Comparative genomic hybridization detected nonrandom chromosomal gains and losses in three pairs of sister myeloma cell lines established from bone marrow- and pleural effusion-cells from the same patient , 2003 .